kevindenver, well said. Most importantly, CEO didn't line his pockets...he built cash reserves for the company. That shows confidence.

JMHO,
vg_future

Got it. We are all eagerly waiting...so, any hint of NEWS will be exciting.

-vg_future

Interesting post from ST. Thanks to Monregi on ST for posting this.

https://stocktwits.com/monregi/message/533098903
What was Nell doing yesterday at Citi HQ?

link please?

I would take it with a grain of salt unless a link (entire list) with the exhibits/posters is provided. The ST message just had a screen shot of just one page (maybe). Also, there is always a possibility of a late breaking session or something to that effect.

JMHO,
vg_future

No such restrictions in/on TDAmeritrade. Could be platform specific.

NP. Actually Talon posted it before me and I was just pointing at some submission references as a part of the discussion around how new the article is.

yes, agreed.

The article seems like a new submission... From the article:
Also, there are references in there from Sep, 2022 (so, it cannot be years old as some seem to say/hint)


Siddiqui, T., Bhatt, L.K. Targeting Sigma-1 Receptor: A Promising Strategy in the Treatment of Parkinson’s Disease. Neurochem Res (2023). https://doi.org/10.1007/s11064-023-03960-6

Download citation


Received
01 March 2023

Revised
16 May 2023

Accepted
23 May 2023

Published
31 May 2023


DOI
https://doi.org/10.1007/s11064-023-03960-6


-vg_future

ignatiusrielly35, sorry for the delayed response. Yes, it was a new position and it is interesting. Let's see what happens by tomorrow.

-vg_future

Steady_T, sorry I missed this post earlier. You might have already noticed that the open interest has increased by the volume (around 3K), but just clarifying....
the 18 were the open interest from the earlier day and the 3K volume on that day (not reflected in the open interest when you checked I think) are the new ones that are opened. I am not sure why the position was opened...anticipation of NEWS around earnings or to provide additional leverage for some new long positions or short covering (maybe). Let's see where the stock closes by tomorrow (option expiration).

-vg_future

Yes, I think that is the connection that led to the conversation on LinkedIn that the ST member pulled (I couldn’t paste the actual conversation from LinkedIn) . Also, I think the market cap is more close to 10 Billion or more than that (I could be wrong though).

-vg_future

From ST, found this interesting conversation...not sure if this is posted here already. Posting as is...hopefully they don't mind this reposting/sharing here.

https://stocktwits.com/monregi/message/527970991

monregi
6:36?AM
$AVXL Just found this on Linkedin. Otsuka holdings, a japanese pharma company contacted Nell Rebowe about a month ago. The bets for associating with anavex begin to rise...
Bullish


3Comments

0Reshares

45Likes


AVXL Since Post:
$0.5401
(5.69%)
Then:$9.50
Now:$8.96

AntonioChigurh
8:59?AM
@monregi $20B MC Japanese company. Interesting.

Hoping for a bigger more powerful partner





monregi
9:50?AM
@AntonioChigurh what we have found is a rare public slip-up between ex-work colleagues, I'm sure there are many more contacts behind that we don't know about...
Bullish



1


AVXL4theWin
10:11?AM
@AntonioChigurh @monregi Anavex is required to partner with Japanese based pharma if they want to sell in Japan. There will bigger partners for other bigger territories for AD, PD.

Thanks Simonizer. Could this be due to grants (option/RSU) vesting?

Hoskuld, yes, in a way and there was some additional light shed on Parkinson as well. One big difference is that Tom spoke to Anavex (so, more like a Q&A or discussion) as opposed to the analysis based on what came out in the PR and CC report. Looks like Tom felt confident after he spoke which is good. Many smart posters on this board (as you mentioned) came to the same conclusions as Tom, but there are always posters who try to downplay the analysis and create the noise.

JMHO,
vg_future

Thanks Boopka for posting this. A real use of the board's time and space would be a discussion on what Tom was able to gather from the company after the CC and ponder on the possibilities. I think it is very encouraging and the developments from the company will unravel soon for all to see.
I also think that we will get some additional commentary from the analysts and maybe an updated target price soon.

-vg_future

tredenwater2, I would think so (partner would have something claim as well) atleast from planning/intention perspective even it doesn't turn out to be a combo. I think, Anavex's drug can pull it off without a combo, but it doesn't hurt to enhancce the value and offering with combo treatments.
Shorts would get the rough end of the stick even if the partners wouldn't come onboard before then. But, it would be fun to watch some of the manipulators taking it hard....redemption. I wish few things happen faster/sooner, but investment doesn't dictate science timeline. Hoping that the treatment comes for the rescue of many suffering patients sooner.

-vg_future

Great call today with lot of reassurance (P4 vs P3, partnerships). Also, since there were no questions by analysts, Missling went through some additional questions sent to the company (via email or IR phone conversations)..which is good.
Folks can start investing/betting as per their comfort.

JMHO,
vg_future

Thanks for checking and confirming Kentucky123. That is a pretty hefty volume increase.....hoping for something real big.

-vg_future

I don't think the open interest (as far as I can remember) was big on that strike price. So, the volume must be opening position. It could slightly off if some positions are being sold into the volume. We would know what the numbers are tomorrow or on Monday when they update the open interest.
Also, the bid and ask has gone up by 5 cents which could mean it is a purchase.

-vg_future

High volume (over 3K) on May 19th $9.50 strike price calls. Some pretty heavy betting going on.

-vg_future

Nice updates on the ST regarding the presentation including ALS potentially being the undisclosed target.
I still believe that there will be another update from Anavex this week.

JMHO,
vg_future

It is possible that there could be some unpublished data/analysis in there…so, we might have to wait until Monday…hopefully for a PR release. Just my WAG (Wild A$$ Guess).

It is also possible that the unpublished data is what Anavex announced on Thursday last week. Still my WAG.

Isn’t he still in Australia or maybe he is just back. So, he can do a PR and call following it here in US (maybe some updates from Australia as well). He doesn’t have to (or maybe cannot) go to this conference.

-vg_future

That is possible and is typical of hiring announcements/statements. But, Anavex announcing it now (vs when it actually occurred), could it be that the company is setting the stage for the authenticity and validation of the data (so that Wall Street can see it) before it is announced?

TIA,
vg_future

Coudn't agree more. Any insights on why it is listed as "Late Breaking Oral...." (as mentioned by or that is a typical way how oral presentations are qualified at CTAD? I think that means a lot and shows confidence in results.

-vg_future

Yes, got it (I just realized that today's closing price is less than the award price of 10.09 ).
I was referring to the amount of around 500K which seemed big and most likely tied with something key/significant (IMO) milestone. Hoping for some good NEWS.

-vg_future

The option grants (50K @ 10.09) seem pretty big, so I would say they are tied with some event (not sure which one...could be completion of AD or PDD OLE data ready or submission to FDA...just guesses). I am expecting to see one more big one that goes to Dr.Missling.
Hoping for NEWS soon.

-vg_future

Exactly. These patients definitely need a break and Anavex is giving it to them....through their medicine and proven results (personally verified by the patients themselves) and some additional hope (never hurts to see the brighter prospects).

-vg_future

Great post tradeherpete! Couldn't agree more or said it any other way. Excellent!

-vg_future

Bourbon...if I may interject....I understand that we are/were all hoping for better NEWS/results by now, but there is progress if you look at it. The update Meeting with FDA for discussing is encouraging...it is not "Planned to meet" anymore. I guess things are moving along now....into actions.
Also, the cash position of $153.3 million is encouraging...looks like we have ended up with more money than last quarter in spite of spending over $10 million this quarter.

Bright/interesting tidbits from this morning's PR

From PR:
- Meeting with FDA for discussing ANAVEX®2-73 Parkinson’s disease program including pivotal Phase 3 study.

(please note the "Meeting" word as opposed to "Planned to meet"...so, this is actively happening now...hopefully more color will be provided during the CC this evening.

- Cash and cash equivalents of $153.3 million on March 31, 2022

(cash and cash equivalents were at 151.1 million at the end of Dec, 2021....so that is an increase of 2.2 million in spite of burn rate of 10.9 million roughly...effectively making it a 13.1 million increase in cash...revenue, grant or otherwise)

There are other highlights as well, but these 2 caught my eye.

Good luck to the long shareholders.

-vg_future

end2war, good explanation. Makes sense.

OT - SAVA related Citizen's petition rejected by FDA on kind of technicality..I think petition didn't present any facts, but has instead requested FDA do the fact finding for the allegations. FDA cannot investigate what the petition is requesting and hence denied the request. SEC investigation on SAVA is still on though.

Our AVXL has a clean chit and hope the market recognizes that fact and gives due respect.

-vg_future

RedShoulder, yes, I agree. There are some really nice posts over there. Good to hear about the background on "Mighty Kurtz". The info that he afforded is very valuable and encouraging.

-vg_future

From stocktwits...poster and the post seemed to be genuine...no way for me to check/confirm though. But, FWIW (I underlined part where he quoted correspondence/communication with IR)


Veliger

I fully expect we see a lot more behind the curtain tomorrow. More transparency with what is going on with PDD (per IR this morning), and where the numerous, other trial starts are (i.e. Fragile X, ultra rare diseases). At a minimum there will be definitive answers for RETT filing strategy and when. Any dialogue or Q&A around partnership would also be welcome. I’d love to see this serve as catalyst for some upgrades, following avatar data and strategy.

The points seem to be touching the most common questions on the board. Thanks to "Veliger" for the post.

-vg_future

Thanks a bunch RedShoulder. Much appreciated.
As we see here...the answer is clear, but unfortunately, the lapse in putting a complete statement together and assuming that it will be understood gave the A##F an opening to spew his junk. Great missed opportunity for the company. However, I liked the part where the IR guy said "There will be a clear and concrete plan laid out for the company". I am itching to go out on a limb and say, probably what they are going to share next week from plans perspective will make this week a non-issue and hence there might be slight attitude from the company's perspective that A##F would be taken care of while long term shareholders and the "CNS patient" community are being rewarded.

-vg_future

Thanks RedShoulder. Please post the second part of the conversation...with more meat. I don't want to steal the flow from you....I really liked part of the last bit in there.."concrete plan laid out for the company"

-vg_future

Thanks to Missling for putting out the clarification...it answered my earlier question (directly/indirectly) about the change in phase 2 to 3 and change of the end point...

from the IBD article.

https://finance.yahoo.com/m/e06e7d2d-237e-359d-954b-618beecb551f/anavex-ceo-says-inaccurate.html


"The company also decided then to upgrade the study to a Phase 3 test based on confidence in earlier studies, Missling said. The new measures selected offer a better look at the drug's benefit, he said."

Straight from the horses mouth.

-vg_future

Okay, got it.

-vg_future